Korro Bio Adds KRRO-111 for AATD Treatment
Korro Bio announced the addition of KRRO-111 for the potential treatment of AATD to its pipeline of therapeutic programs in development. KRRO-111 is a proprietary GalNAc-conjugated oligonucleotide that is delivered subcutaneously to the liver cells, where it is engineered to co-opt the hepatocytes' endogenous Adenosine Deaminase Acting on RNA enzyme and repair a pathogenic single nucleotide variant on AAT mRNA to restore production of normal AAT protein.
